Vor Bio Says Telitacicept Achieves Primary Endpoint in Phase 3 Kidney Disease Study
MT Newswires Live
Aug 27
Vor Bio (VOR) said Wednesday its collaborator RemeGen achieved the primary endpoint in a phase 3 clinical study evaluating telitacicept in adults with IgA nephropathy in China.
The study, which enrolled 318 adult patients, demonstrated a 55% reduction in urine protein-to-creatinine ratio after 39 weeks, meeting the primary endpoint, the company said.
Telitacicept showed a favorable safety profile in the trial, the biotechnology company said.
RemeGen plans to submit a biologics license application for IgAN to China's National Medical Products Administration, Vor Bio said.
Shares of the company were up 1% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.